A new tool evaluates the relationship between the Mediterranean diet and health in preschoolers
24 January 2025Ramón Areces Foundation Scholarships for Postdoctoral Studies. XXXVII Call for Further Studies Abroad in Life and Material Sciences
28 January 2025
The Seville Foundation 'La Colmena' announces the winning projects of its 2024 Research Grants, an annual initiative aimed at supporting innovative research in the fields of Neurodegeneration, Cancer and Longevity
La Colmena Foundation is a non-profit organization from Seville. Its main objectives are: promote, coordinate, disseminate and finance initiatives and activities of a technological, scientific, educational, environmental, cultural, social and training nature.
'2024 Research Grants' is one of its annual initiatives aimed at supporting innovative research, this time in the fields of Neurodegeneration, Cancer and Longevity.
«Role of the major histocompatibility complex as a prognostic and predictive biomarker in early and advanced stages of colorectal cancer»
The group project of the IIS Aragón 'Cancer Heterogeneity and Immunomics' (GIIS110), led by Dr. Rebeca Sanz Pamplona, is one of the scholarship recipients.
The objective of the project is analyze the role of HLA molecules as prognostic and predictive biomarkers in colorectal cancer, evaluating their impact on immune response and clinical prognosis. In addition, it seeks to explore their potential to improve treatment personalization through immunotherapy and NK cell therapies.
«New metabolomic approaches for monitoring monoclonal gammopathy of undetermined significance: A step forward towards precision medicine»
The second award-winning project is led by Dr. Leonor Puchades Carrasco from the Platform for Support for Drug Development and Innovation (PADIM) of the La Fe Health Research Institute (IIS La Fe).
The objective of the Project is Identify noninvasive biomarkers through metabolomic approaches that allow predicting the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM).
Source: The Beehive Foundation
